Regenerative Treatments
for Ophthalmic Diseases
Neuroptika’s mission is to improve patients’ lives by developing novel regenerative therapies for ophthalmic diseases
NRO-1
A POTENTIAL DISEASE MODIFYING TREATMENT
Neuroptika is leveraging insights into the relationship between nerve degeneration and ophthalmic diseases to develop transformative treatments.
NRO-1, Neuroptika's lead therapy, is a nerve regenerative therapeutic that can treat the underlying cause of degenerative ophthalmic diseases.
Corneal Nerve Degeneration
Retinal Ganglion Cell Degeneration
Axonal regeneration of corneal sensory nerves
2. ACCELERATES
Neurite elongation in trigeminal ganglion (peripheral) and retinal ganglion (central) cells
3. PROMOTES
1. RELEASES
Glial cell-derived neurotrophic factor (GDNF)
NRO-1 PROGRAMS
NRO-1 has successfully completed a Phase 1 study. A Phase 2 study for dry eye disease is ongoing.